Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies

Nature Reviews Cancer

Volumn 16, Issue 2, 2016, Pages 99-109

  Delbridge, Alex R D ^a   Grabow, Stephanie ^a   Strasser, Andreas ^a   Vaux, David L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BCL 2 INHIBITOR; BH3 PROTEIN; BIM PROTEIN; NAVITOCLAX; PNT 2258; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN INHIBITOR; S 055746; UNCLASSIFIED DRUG; VENETOCLAX; ABT-737; BIPHENYL DERIVATIVE; C22ORF29 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; CARCINOGENESIS; CELL DEATH; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; ENDOPLASMIC RETICULUM; FOOD AND DRUG ADMINISTRATION; GENETIC CONSERVATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MULTIGENE FAMILY; NEOPLASMS; PROCEDURES; PROTO ONCOGENE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; CELL DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; MICE; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84956630703     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2015.17     Document Type: Review

References (194)

1. AbbVie Media Room. Venetoclax receives breakthrough therapy designation in relapsed or refractory chronic lymphocytic leukemia in previously treated patients with the 17p deletion genetic mutation. http://abbvie.mediaroom.com/2015-05-06-Investigational-Medicine-Venetoclax-Receives-Breakthrough-Therapy-Designation-in-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-in-Previously-Treated-Patients-with-the-17p-Deletion-Genetic-Mutation (updated 6 May 2015).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
4. Hotchkiss, R. S., Strasser, A., McDunn, J. E. & Swanson, P. E. Cell death. N. Engl. J. Med. 361, 1570-1583 (2009).
5. Delbridge, A. R. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22, 1071-1080 (2015).
6. Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714 (2013).
7. Moldoveanu, T., Follis, A. V., Kriwacki, R. W. & Green, D. R. Many players in BCL-2 family affairs. Trends Biochem. Sci. 39, 101-111 (2014).
8. Davids, M. S. & Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 30, 3127-3135 (2012).
9. Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18, 157-164 (2008).
10. Levine, B., Sinha, S. & Kroemer, G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4, 600-606 (2008).
11. Kerr, J. F. R., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257 (1972).
12. Varmus, H. E. The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 18, 553-612 (1984).
13. Fukuhara, S. & Rowley, J. D. Chromosome 14 translocations in non-Burkitt lymphomas. Int. J. Cancer 22, 14-21 (1978).
14. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-1099 (1984).
15. Cleary, M. L. & Sklar, J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl Acad. Sci. USA 82, 7439-7443 (1985).
16. Tsujimoto, Y. & Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. USA 83, 5214-5218 (1986).
17. Cleary, M. L., Smith, S. D. & Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47, 19-28 (1986).
18. H on chromosome 14 and near a transcriptional unit on 18. Cell 41, 899-906 (1985).
19. Cook, W. D., Metcalf, D., Nicola, N. A., Burgess, A. W. & Walker, F. Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell 41, 677-683 (1985).
20. Wheeler, E. F., Askew, D., May, S., Ihle, J. N. & Sherr, C. J. The v-fms oncogene induces factor-independent growth and transformation of the interleukin-3-dependent myeloid cell line FDC-P1. Mol. Cell. Biol. 7, 1673-1680 (1987).
21. Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440-442 (1988).
22. McDonnell, T. J. et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79-88 (1989).
23. Nuñez, G. et al. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc. Natl Acad. Sci. USA 86, 4589-4593 (1989).
24. Nuñez, G. et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144, 3602-3610 (1990).
25. Tsujimoto, Y. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4, 1331-1336 (1989).
26. Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D. & Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336 (1990).
27. Strasser, A. et al. Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr. Top. Microbiol. Immunol. 166, 175-181 (1990).
28. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O. & Korsmeyer, S. J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67, 879-888 (1991).
29. Strasser, A., Harris, A. W. & Cory, S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67, 889-899 (1991).
30. Chen-Levy, Z., Nourse, J. & Cleary, M. L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell. Biol. 9, 701-710 (1989).
31. Chen-Levy, Z. & Cleary, M. L. Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J. Biol. Chem. 265, 4929-4933 (1990).
32. Haldar, S., Beatty, C., Tsujimoto, Y. & Croce, C. M. The bcl-2 gene encodes a novel G protein. Nature 342, 195-198 (1989).
33. Monaghan, P. et al. Ultrastructural localization of BCL-2 protein. J. Histochem. Cytochem. 40, 1819-1825 (1992).
34. Jacobson, M. D. et al. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361, 365-369 (1993).
35. Lithgow, T., van Driel, R., Bertram, J. F. & Strasser, A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum and the outer mitochondrial membrane. Cell Growth Differ. 5, 411-417 (1994).
36. Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333 (1990).
37. McDonnell, T. J. & Korsmeyer, S. J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349, 254-256 (1991).
38. Strasser, A., Harris, A. W. & Cory, S. Em-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 8, 1-9 (1993).
39. Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602 (1983).
40. Gauwerky, C. E., Hoxie, J., Nowell, P. C. & Croce, C. M. Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma. Oncogene 2, 431-435 (1988).
41. Askew, D. S., Ashmun, R. A., Simmons, B. C. & Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922 (1991).
42. Fanidi, A., Harrington, E. A. & Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554-556 (1992).
43. Bissonnette, R. P., Echeverri, F., Mahboubi, A. & Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552-554 (1992).
44. Reed, J. C., Cuddy, M., Slabiak, T., Croce, C. M. & Nowell, P. C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336, 259-261 (1988).
45. Strasser, A. et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 88, 8661-8665 (1991).
46. Vaux, D. L., Aguila, H. L. & Weissman, I. L. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol. 4, 821-824 (1992).
47. Strasser, A., Harris, A. W., Huang, D. C. S., Krammer, P. H. & Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14, 6136-6147 (1995).
48. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (1998).
49. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 65, 233-243 (1991).
50. Sulston, J. E. & Horvitz, H. R. Postembryonic cell lineages of the nematode Caenorhabditis elegans. Dev. Biol. 56, 110-156 (1977).
51. Ellis, H. M. & Horvitz, H. R. Genetic control of programmed cell death in the nematode C. elegans. Cell 44, 817-829 (1986).
52. Vaux, D. L., Weissman, I. L. & Kim, S. K. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 258, 1955-1957 (1992).
53. Hengartner, M. O. & Horvitz, H. R. C.elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76, 665-676 (1994).
54. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M. & Horvitz, H. R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1b-converting enzyme. Cell 75, 641-652 (1993).
55. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004).
56. Kvansakul, M. & Hinds, M. G. Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis. 4, e909 (2013).
57. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. & Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2. Proc. Natl Acad. Sci. USA 90, 3516-3520 (1993).
58. Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608 (1993).
59. Lin, E. Y., Orlofsky, A., Berger, M. S. & Prystowsky, M. B. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J. Immunol. 151, 1979-1988 (1993).
60. Gibson, L. et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13, 665-675 (1996).
61. Inohara, N. et al. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J. Biol. Chem. 273, 32479-32486 (1998).
62. Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619 (1993).
63. Kiefer, M. C. et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374, 736-739 (1995).
64. Farrow, S. N. et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374, 731-733 (1995).
65. Ke, F. et al. BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ. 19, 915-925 (2012).
66. Hsu, S. Y., Kaipia, A., McGee, E., Lomeli, M. & Hsueh, A. J. W. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc. Natl Acad. Sci. USA 94, 12401-12406 (1997).
67. L and Bcl-2, displaces Bax and promotes cell death. Cell 80, 285-291 (1995).
68. L proteins. J. Biol. Chem. 272, 30866-30872 (1997).
69. Boyd, J. M. et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11, 1921-1928 (1995).
70. Wang, K., Yin, X.-M., Chao, D. T., Milliman, C. L. & Korsmeyer, S. J. BID: a novel BH3 domain-only death agonist. Genes Dev. 10, 2859-2869 (1996).
71. Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081 (2008).
72. Chen, L. et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
73. Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859 (2007).
74. Kuwana, T. et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17, 525-535 (2005).
75. L. EMBO J. 16, 1686-1694 (1997).
76. O'Connor, L. et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384-395 (1998).
77. Puthalakath, H. et al. Bmf: a pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829-1832 (2001).
78. Oda, E. et al. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058 (2000).
79. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
80. Han, J. et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl Acad. Sci. USA 98, 11318-11323 (2001).
81. Schweers, R. L. et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl Acad. Sci. USA 104, 19500-19505 (2007).
82. Doerflinger, M., Glab, J. A. & Puthalakath, H. BH3-only proteins: a 20-year stock-take. FEBS J. 282, 1006-1016 (2015).
83. Veis, D. J., Sorenson, C. M., Shutter, J. R. & Korsmeyer, S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229-240 (1993).
84. Yamamura, K. et al. Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res. 56, 3546-3550 (1996).
85. Nakayama, K.-i. et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 261, 1584-1588 (1993).
86. Bouillet, P., Cory, S., Zhang, L.-C., Strasser, A. & Adams, J. M. Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev. Cell 1, 645-653 (2001).
87. Motoyama, N. et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 267, 1506-1510 (1995).
88. Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K. & Korsmeyer, S. J. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 14, 23-27 (2000).
89. Thomas, R. L. et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27, 1365-1377 (2013).
90. Wang, X. et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27, 1351-1364 (2013).
91. Arbour, N. et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 28, 6068-6078 (2008).
92. Opferman, J. et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101-1104 (2005).
93. Delbridge, A. R., Opferman, J. T., Grabow, S. & Strasser, A. Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. Blood 125, 3273-3280 (2015).
94. Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671-676 (2003).
95. Peperzak, V. et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290-297 (2013).
96. Vikstrom, I. et al. Mcl-1 is essential for germinal center formation and B cell memory. Science 330, 1095-1099 (2010).
97. Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735-1738 (1999).
98. Puthalakath, H. et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129, 1337-1349 (2007).
99. Erlacher, M. et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 203, 2939-2951 (2006).
100. Egle, A., Harris, A. W., Bouillet, P. & Cory, S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA 101, 6164-6169 (2004).
101. Tagawa, H. et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24, 1348-1358 (2005).
102. Richter-Larrea, J. A. et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116, 2531-2542 (2010).
103. Yin, X.-M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400, 886-891 (1999).
104. Li, H., Zhu, H., Xu, C.-J. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (1998).
105. Luo, X., Budlhardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (1998).
106. Jost, P. J. et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460, 1035-1039 (2009).
107. Lindsten, T. et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389-1399 (2000).
108. Knudson, C. M., Tung, K. S. K., Tourtellotte, W. G., Brown, G. A. J. & Korsmeyer, S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270, 96-99 (1995).
109. Rathmell, J. C., Lindsten, T., Zong, W.-X., Cinalli, R. M. & Thompson, C. B. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat. Immunol. 3, 932-939 (2002).
110. Mason, K. D. et al. Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proc. Natl Acad. Sci. USA 110, 2599-2604 (2013).
111. Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
112. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R. & Thompson, C. B. BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 15, 1481-1486 (2001).
113. Newmeyer, D. D., Farschon, D. M. & Reed, J. C. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79, 353-364 (1994).
114. Liu, X., Kim, C. N., Yang, J., Jemmerson, R. & Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86, 147-157 (1996).
115. Yang, J. et al. Prevention of apoptosis by Bcl-2 - release of cytochrome c from mitochondria blocked. Science 275, 1129-1132 (1997).
116. Kluck, R. M., Bossy-Wetzel, E., Green, D. R. & Newmeyer, D. D. The release of cytochrome c from mitochondria - a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136 (1997).
117. L during apoptosis. Proc. Natl Acad. Sci. USA 94, 3668-3672 (1997).
118. Antonsson, B. et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 277, 370-372 (1997).
119. Marsden, V. et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419, 634-637 (2002).
120. Ekert, P. G. et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J. Cell Biol. 165, 835-842 (2004).
121. L-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997).
122. Suzuki, M., Youle, R. J. & Tjandra, N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645-654 (2000).
123. L/Bim fragment complex: implications for Bim function. Immunity 19, 341-352 (2003).
124. Czabotar, P. E. et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152, 519-531 (2013).
125. Dewson, G. & Kluck, R. M. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J. Cell Sci. 122, 2801-2808 (2009).
126. Kale, J., Liu, Q., Leber, B. & Andrews, D. W. Shedding light on apoptosis at subcellular membranes. Cell 151, 1179-1184 (2012).
127. Leber, B., Lin, J. & Andrews, D. W. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12, 897-911 (2007).
128. Monni, O. et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90, 1168-1174 (1997).
129. Olejniczak, E. T. et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol. Cancer Res. 5, 331-339 (2007).
130. Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944-13949 (2005).
131. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
132. L protects cancer cells from p53-mediated apoptosis. Oncogene 11, 1389-1394 (1995).
133. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55, 2576-2582 (1995).
134. Jin-Song, Y. et al. Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 113, 810-814 (2011).
135. L gene in human gastric adenomas and carcinomas. Int. J. Cancer 68, 727-730 (1996).
136. Watanabe, J. et al. Bcl-xL overexpression in human hepatocellular carcinoma. Int. J. Oncol. 21, 515-519 (2002).
137. Castilla, C. et al. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 147, 4960-4967 (2006).
138. Shimizu, S. et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 52, 698-704 (2010).
139. Chen, J. et al. miR-193b regulates Mcl-1 in melanoma. Am. J. Pathol. 179, 2162-2168 (2011).
140. Gong, J. et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32, 3071-3079 (2013).
141. Garrison, S. P. et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol. Cell. Biol. 28, 5391-5402 (2008).
142. Rampino, N. et al. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967-969 (1997).
143. Meijerink, J. P. P. et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91, 2991-2997 (1998).
144. Strasser, A., Harris, A. W., Jacks, T. & Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79, 329-339 (1994).
145. Villunger, A. et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302, 1036-1038 (2003).
146. Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328 (2003).
147. Erlacher, M. et al. BH3-only proteins Puma and Bim are rate-limiting for γ-radiation and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106, 4131-4138 (2005).
148. Michalak, E. M., Villunger, A., Adams, J. M. & Strasser, A. In several cell types the tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 15, 1019-1029 (2008).
149. Happo, L. et al. Maximal killing of lymphoma cells by DNA-damage inducing therapy requires not only the p53 targets Puma and Noxa but also Bim. Blood 116, 5256-5267 (2010).
150. Kuribara, R. et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitor. Mol. Cell. Biol. 24, 6172-6183 (2004).
151. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA 103, 14907-14912 (2006).
152. Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires Bim and can be enhanced by BH3 mimetics. PLoS Med. 4, 1681-1689 (2007).
153. Costa, D. B. et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, e315 (2007).
154. Gong, Y. et al. Induction of BIM Is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
155. Cragg, M. S., Jansen, E. S., Cook, M., Strasser, A. & Scott, C. L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 118, 3651-3659 (2008).
156. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
157. Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521-528 (2012).
158. Chonghaile, T. N. et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334, 1129-1133 (2011).
159. Vo, T. T. et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344-355 (2012).
160. Reed, J. C. et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50, 6565-6570 (1990).
161. Lai, J. C. et al. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol. Cancer Ther. 2, 1031-1043 (2003).
162. Konopleva, M. et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420 (2008).
163. Lei, X. et al. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J. 20, 2147-2149 (2006).
164. Varadarajan, S. et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 20, 1475-1484 (2013).
165. van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
166. Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7, 989-1000 (2008).
167. L, an inhibitor of programmed cell death. Nature 381, 335-341 (1996).
168. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
169. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
170. Vogler, M. et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 16, 1030-1039 (2009).
171. Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149-1159 (2010).
172. Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a Phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488-496 (2012).
173. Oakes, S. R. et al. Breast cancer special feature: sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl Acad. Sci. USA 109, 2766-2771 (2012).
174. Ackler, S. et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother. Pharmacol. 66, 869-880 (2010).
175. Shoemaker, A. R. et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277 (2008).
176. Mason, K. D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173-1186 (2007).
177. Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943-951 (2007).
178. L inhibitor. Nat. Chem. Biol. 9, 390-397 (2013).
179. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
180. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1513257 (2015).
181. Roberts, A. W. et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 lymphoid malignancies. Br. J. Haematol. 170, 669-678 (2015).
182. Vandenberg, C. J. & Cory, S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121, 2285-2288 (2013).
183. low profile and synergizes with other antineoplastic agents. Clin. Cancer Res. 17, 5973-5981 (2011).
184. Vaillant, F. et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24, 120-129 (2013).
185. Leverson, J. D. et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 6, e1590 (2015).
186. Xiang, Z. et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J. Clin. Invest. 120, 2109-2118 (2010).
187. Glaser, S. et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120-125 (2012).
188. Kelly, G. L. et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28, 58-70 (2014).
189. L is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124, 3939-3946 (2014).
190. Koss, B. et al. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 122, 1587-1598 (2013).
191. Cragg, M. S., Harris, C., Strasser, A. & Scott, C. L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 9, 321-326 (2009).
192. Deng, J. et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-185 (2007).
193. Bouillet, P. et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922-926 (2002).
194. Shibue, T. et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 17, 2233-2238 (2003).